Physician profile
Daniel Anthony Rakowski
NPI 1275504029
$7,503.40
in general payments reported to CMS, 2019-2025
35 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $254 · 2021: $363 · 2022: $1,070 · 2023: $1,577 · 2024: $1,473 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,422 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,422.04 |
| Education | $210.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,008.61 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $902.44 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $792.08 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $429.54 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $417.62 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $404.87 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $308.64 | 2019-2024 | Auryxia, Vafseo |
| Mallinckrodt Enterprises LLC | $271.62 | 2019 | |
| Vifor Pharma, INC. | $243.63 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $215.33 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $211.78 | 2022-2025 | Benlysta, Shingrix |
| Mallinckrodt Hospital Products INC. | $205.81 | 2020-2024 | Acthar |
| Daiichi Sankyo INC. | $191.17 | 2019-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $189.27 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $183.25 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $172.22 | 2025 | |
| Ardelyx, INC. | $164.34 | 2023-2025 | Ibsrela |
| Stryker Corporation | $154.98 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $139.46 | 2023-2025 | Ozempic, Rybelsus, Rivfloza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.35 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $121.87 | 2019-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $103.66 | 2022-2025 | Tarpeyo |
| Shield Therapeutics INC | $102.29 | 2024-2025 | |
| Scpharmaceuticals INC. | $93.72 | 2025 | |
| Ani Pharmaceuticals, INC. | $79.25 | 2022-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $48.93 | 2019-2022 | |
| Genentech USA, INC. | $47.21 | 2025 | Gazyva |
| Alexion Pharmaceuticals, INC. | $43.62 | 2024-2025 | Ultomiris |
| Lilly USA, LLC | $41.03 | 2023-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $29.86 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.50 | 2025 | |
| Ascendis Pharma Endocrinology INC | $20.45 | 2025 | Yorvipath |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rakowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.